Literature DB >> 1446480

Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia.

A G Hoffman1, M G Lawrence, F P Ognibene, A F Suffredini, G Y Lipschik, J A Kovacs, H Masur, J H Shelhamer.   

Abstract

We assessed qualitative and quantitative differences in surfactant lipid composition of bronchoalveolar lavage (BAL) fluid in patients with acquired immune deficiency syndrome (AIDS) and Pneumocystis carinii (PC) pneumonia. Five normal volunteers and 27 patients with human immunodeficiency virus (HIV) infection underwent BAL for evaluation of possible pulmonary infection. Bronchoalveolar lavage studies in eight patients were negative for PC organisms, and 19 were positive. Pneumocystis carinii pneumonia was graded (mild vs moderate to severe) by initial alveolar-arterial oxygen gradient. Bronchoalveolar lavage fluid was centrifuged, the lipids were extracted from the supernatant, and total lipid profiles of dephosphorylated glycerolipids were analyzed as trimethylsilylether derivatives by high temperature gas-liquid chromatography. Phospholipase A2 levels were determined using a radiolabeled E coli membrane method. Compared to the normal volunteers (109 +/- 13 micrograms/5 ml) and the PC negative group (107 +/- 13 micrograms/5 ml), total BAL lipid was reduced for both the mild PC pneumonia group (73 +/- 10 micrograms/5 ml) and the moderate to severe PC pneumonia group (46 +/- 4 micrograms/5 ml). There was a parallel reduction of diacylglycerol lipids: normal volunteers, 52 +/- 7 micrograms/5 ml; PC negative, 52 +/- 9 micrograms/5 ml; mild PC pneumonia, 35 +/- 7 micrograms/5 ml; and moderate to severe PC pneumonia, 15 +/- 2 micrograms/5 ml. Phospholipase A2 activity in moderate to severe PC pneumonia was twice that of the PC negative patients, and 30 times that for normals. The data demonstrate a marked diminution in surfactant glycerophospholipid in patients with AIDS and PC pneumonia and suggest a potential role for surfactant abnormality in the pathophysiology of this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446480     DOI: 10.1378/chest.102.6.1730

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  15 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 2.  Pneumocystis.

Authors:  Francis Gigliotti; Andrew H Limper; Terry Wright
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

3.  Use of natural surfactant in an HIV-infected infant with Pneumocystis carinii pneumonia.

Authors:  S C Marriage; H Underhill; S Nadel
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

Review 4.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

5.  Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.

Authors:  T W Wright; R H Notter; Z Wang; A G Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Sterols of Pneumocystis carinii hominis organisms isolated from human lungs.

Authors:  E S Kaneshiro; Z Amit; J Chandra; R P Baughman; C Contini; B Lundgren
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

7.  C27 to C32 sterols found in Pneumocystis, an opportunistic pathogen of immunocompromised mammals.

Authors:  E S Kaneshiro; M A Wyder
Journal:  Lipids       Date:  2000-03       Impact factor: 1.880

Review 8.  The lipids of Pneumocystis carinii.

Authors:  E S Kaneshiro
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

9.  Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat.

Authors:  W R Rice; F M Singleton; M J Linke; P D Walzer
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

10.  Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages.

Authors:  D M O'Riordan; J E Standing; K Y Kwon; D Chang; E C Crouch; A H Limper
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.